EaglePicher Medical Power Introduces New Contego 440 mAh Lithium-ion Battery

New Contego® 440: An Implantable & Rechargeable Large-capacity, Small-footprint Cell Utilizing a Proven Chemistry that Has Extensive Cycling Data Across Multiple Medical Customers

EaglePicher® Medical Power, a division of EaglerPicher Technologies, announced today the launch of the all-new Contego® 440 mAh battery, an implantable grade, lightweight, and high-energy-density lithium-ion battery.

According to EaglePicher, the rechargeable off-the-shelf Contego 440 offers superior rate capability and cycle life and is manufactured in a certified ISO13405 facility.

The Contego 440 battery comes in a fully welded hermetically sealed stainless-steel case and can be used across a range of medical applications including neuromodulators, drug pumps, body fluid pumps, and cardiac monitors. The individual battery weighs just 19.1g and carries a voltage range of 3.0 to 4.1V. While the Contego 440 is available off-the-shelf, additional options include custom terminations, application-specific documentation for FDA submission, application-specific testing, custom markings, and custom packaging.

“We’re extremely pleased to introduce the Contego 440 as part of our growing line of mission-critical medical device batteries,” commented Chris Huntington, EaglePicher Medical Power’s President. “The team at EaglePicher Medical Power is committed to developing the latest technology innovations to fuel medical advancement, treatment protocols and improve quality of life. With the new Contego 440, we’ve succeeded in delivering more energy in a small, lightweight cell, while never compromising safety.”

EaglePicher has been at the forefront of implantable medical-grade power solutions for over 25 years. The electrochemistry used in Contego lithium-ion batteries, since 2004, is proven in multiple cell sizes and is remarkably robust, without experiencing a single field failure. Over time, demand has grown for batteries like the new Contego 440, which can do more with less of a physical footprint.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”